Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Swedish Orphan Biovitrum AB (publ)
  6. Summary
    SOBI   SE0000872095

SWEDISH ORPHAN BIOVITRUM AB (PUBL)

(SOBI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
06/10/2021 06/11/2021 06/14/2021 06/15/2021 06/16/2021 Date
156.25(c) 156.4(c) 157.1(c) 154.35(c) 155.65(c) Last
667 599 423 617 517 433 509 478 775 912 Volume
+1.07% +0.10% +0.45% -1.75% +0.84% Change
More quotes
Financials
Sales 2021 14 325 M 1 693 M 1 693 M
Net income 2021 2 017 M 238 M 238 M
Net Debt 2021 9 844 M 1 163 M 1 163 M
P/E ratio 2021 22,9x
Yield 2021 -
Sales 2022 15 659 M 1 850 M 1 850 M
Net income 2022 2 450 M 290 M 290 M
Net Debt 2022 6 647 M 785 M 785 M
P/E ratio 2022 18,8x
Yield 2022 -
Capitalization 45 901 M 5 490 M 5 424 M
EV / Sales 2021 3,89x
EV / Sales 2022 3,36x
Nbr of Employees 1 508
Free-Float 61,3%
More Financials
Company
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The CompanyÔÇÖs product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the... 
Sector
Pharmaceuticals
Calendar
06/15 | 03:45amPresentation
More about the company
Ratings of Swedish Orphan Biovitrum AB (publ)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about SWEDISH ORPHAN BIOVITRUM AB (PUBL)
06/01SOBI AT EHA VIRTUAL CONGRESS 2021 : focus on results in PNH and treatment for IT..
AQ
05/25SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Tuesday
MT
05/25APELLIS PHARMACEUTICALSá : Swedish Orphan Biovitrum Receive 'Positive' Results f..
MT
05/25SWEDISH ORPHAN BIOVITRUMá : Apellis Unveil Positive Phase 3 Trial Results For Bl..
MT
05/25SWEDISH ORPHAN BIOVITRUMá : Positive top-line results from the phase 3 PRINCE st..
AQ
05/20SWEDISH ORPHAN BIOVITRUMá : Unveils Positive Data on Anakinra Treatment Against ..
MT
05/20SWEDISH ORPHAN BIOVITRUMá : Early use of anakinra reduces risk of mortality for ..
AQ
05/04SWEDISH ORPHAN BIOVITRUMá : Bulletin from Swedish Orphan Biovitrum's ("Sobi") An..
AQ
05/04SWEDISH ORPHAN BIOVITRUMá : Sobi publishes report for the first quarter 2021
AQ
05/03SOBI AND HELLENIC INSTITUTE FOR THE : anakinra improved overall clinical outcom..
AQ
04/26SWEDISH ORPHAN BIOVITRUMá : Invitation - Presentation of Sobi's Q1 2021 results
AQ
04/13SWEDISH ORPHAN BIOVITRUMá : Sobi Doses First Patient In Phase 3 Trial Of Pediatr..
MT
04/13SWEDISH ORPHAN BIOVITRUMá : First patient dosed in phase 3 XTEND-Kids study with..
AQ
04/08IRLAB's nomination committee proposes Martin Nicklasson as new board member a..
AQ
04/06SWEDISH ORPHAN BIOVITRUMá : Sobi™ publishes 2020 Annual and Sustainability..
AQ
More news
News in other languages on SWEDISH ORPHAN BIOVITRUM AB (PUBL)
04/20AVIS D'ANALYSTES DU JOURá : BMW, Volkswagen, AstraZeneca, Sopra, Ipsen, Grifols,..
04/20STOCK MARKET PARIS : Les marchés baissent aussi, parfois
02/24C'était Jerome Power
02/24AVIS D'ANALYSTES DU JOURá : Stellantis, BNP Paribas, Faurecia, Société Générale,..
02/19Des PMI et des sorcières pour terminer la semaine
More news
Analyst Recommendations on SWEDISH ORPHAN BIOVITRUM AB (PUBL)
More recommendations
Chart SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Duration : Period :
Swedish Orphan Biovitrum AB (publ) Technical Analysis Chart | SOBI | SE0000872095 | MarketScreener
Technical analysis trends SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 158,75 SEK
Last Close Price 155,65 SEK
Spread / Highest target 18,2%
Spread / Average Target 1,99%
Spread / Lowest Target -19,7%
EPS Revisions
Managers and Directors
NameTitle
Guido Oelkers President & Chief Executive Officer
Henrik Stenqvist Chief Financial Officer
Sven Hňkan Bj÷rklund Chairman
Anne Marie de Jonge Schuermans Head-Technical Operations
Ravi Madduri Rao Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
SWEDISH ORPHAN BIOVITRUM AB (PUBL)-7.07%5 465
CSL LIMITED6.96%105 549
WUXI BIOLOGICS (CAYMAN) INC.13.72%65 802
BIOGEN INC.61.76%59 632
SAMSUNG BIOLOGICS CO.,LTD.0.85%49 815
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.21.70%46 132